Dendreon has appointed Rx Mosaic Health’s Lindsay Rocco to executive VP, corporate communications.
The US biotech, which markets prostate cancer vaccine Provenge (sipuleucel-T), said Rocco will be responsible for all communications functions of the company, reporting directly to chair, president and CEO John Johnson.
Rocco was most recently senior VP at healthcare communications agency Rx Mosaic Health, a position she held since February 2010.
She has previous communications experience within the industry too, serving as director, public affairs at Roche, prior to her time at Rx Mosaic Health.
“Lindsay is a seasoned communicator with a deep understanding of the oncology space and a true passion for Dendreon’s mission to help advanced prostate cancer patients lead longer and better lives,” said Johnson.
“Lindsay’s energy and expertise in healthcare communications makes her an ideal addition to our leadership team.”